16 July 2025
: Case report 
Endovascular Embolization in Acquired Hemophilia A: A Case Study Highlighting Diagnostic and Therapeutic Strategies
Challenging differential diagnosis, Management of emergency care, Rare disease
Michail Makris EF 1, Stavroula Bountola EF 2, Vasileios Patriarcheas EF 1, Anastasia Adamou
EF 1, Panagiota Tsiatsiou EF 3, Vasileios Perifanis EF 1, Christos Savopoulos EF 1, Georgia Kaiafa EF 1*
DOI: 10.12659/AJCR.948268
Am J Case Rep 2025; 26:e948268
Table 3 Patient’s progression in correlation with aPTT and FVIII levels. (FVII levels shown to track the administration of recombinant activated human FVII.) * UNITS/DL FVII values reflect total plasma levels and may not indicate true activated FVIIa (rFVIIa) activity. All coagulation factor levels are expressed in IU/dL.
| Day | aPTT (s) | FVIII (IU/dL) | FVII (IU/dL)* | FVIII inhibitor (BU) |
|---|---|---|---|---|
| Day 1 | 136.8 | <1 | 127 | 7.2 |
| Day 6 | 47.0 | 25 | 5535 | Not measured |
| Day 14 | 40.3 | 43 | 2020 | Not measured |
| Day 19 | 36.1 | 63 | 1200 | Not measured |
| Day 23 | 30.5 | 123 | – | Not measured |
| Day 30 | 35.9 | 299 | 276 | 0 |
| Month 4 | 41.5 | 108 | – | 0 |